Evidence map›Paper›PMID 34929761›Full record

Trial reportInternational journal of urology : official journal of the Japanese Urological Association2022

The O'Leary-Sant Interstitial Cystitis Symptom Index is a clinically useful indicator of treatment outcome in patients with interstitial cystitis/bladder pain syndrome with Hunner lesions: A post hoc analysis of the Japanese phase III trial of KRP-116D, 50% dimethyl sulfoxide solution.

Naoki Yoshimura, Takashi Uno, Mitsuru Sasaki, Akira Ohinata, Shigeki Nawata, Tomohiro Ueda

Open access · hybridAbstract readClinical Trial, Phase III
In one paragraph

Trial report in International journal of urology : official journal of the Japanese Urological Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Naoki YoshimuraDepartment of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-8070-1664
Takashi UnoClinical Development Center, Kyorin Pharmaceutical Co., Ltd., Tokyo, Japan.
Mitsuru SasakiClinical Development Center, Kyorin Pharmaceutical Co., Ltd., Tokyo, Japan.
Akira OhinataClinical Development Center, Kyorin Pharmaceutical Co., Ltd., Tokyo, Japan.
Shigeki NawataClinical Development Center, Kyorin Pharmaceutical Co., Ltd., Tokyo, Japan.
Tomohiro UedaDepartment of Urology, Ueda Clinic, Kyoto, Japan.
Kyorin University · JPUniversity of Pittsburgh · US

Funding

Kyorin Pharmaceutical Co., Ltd.
6 · The paper itself

Abstract

objectivesTo evaluate the efficacy of intravesical KRP-116D, 50% dimethyl sulfoxide solution, in interstitial cystitis/bladder pain syndrome patients with Hunner lesions (Hunner-type interstitial cystitis), and to evaluate the correlations between efficacy variables and global response assessment to determine what constitutes a minimal clinically important change.

methodsWe performed a post hoc analysis of the Japanese phase III trial of KRP-116D. Changes at Week 12 from baseline in objective and subjective outcomes were compared between the KRP-116D and placebo groups in Hunner-type interstitial cystitis or non-Hunner-type interstitial cystitis patients. Correlations between efficacy variables at Week 12 and global response assessment were analyzed. Area under the receiver operating characteristic curve and the cut-off value of efficacy valuables were calculated to determine clinically meaningful changes.

resultsThe effectiveness of intravesical treatment with KRP-116D was demonstrated in Hunner-type interstitial cystitis, but not in non-Hunner-type interstitial cystitis patients. Global response assessment was closely correlated with subjective outcomes including O'Leary-Sant Interstitial Cystitis Symptom Index, O'Leary-Sant Interstitial Cystitis Problem Index, and a numeric rating scale for bladder pain, but was less correlated with voiding variables including micturition frequency, voided volume, and maximum voided volume. In the receiver operating characteristic curve analyses, the cut-off value for the O'Leary-Sant Interstitial Cystitis Symptom Index was -5 (sensitivity 81.3%, specificity 83.3%).

conclusionsClinical benefit of intravesical KRP-116D in Hunner-type interstitial cystitis patients was confirmed in this post hoc analysis. A five-point reduction in O'Leary-Sant Interstitial Cystitis Symptom Index is a clinically meaningful indicator for assessing patient satisfaction with KRP-116D treatment in patients with Hunner-type interstitial cystitis.

Indexed as

Cystitis, InterstitialAdministration, IntravesicalDimethyl SulfoxideHumansJapanTreatment OutcomeDimethyl Sulfoxidedimethyl sulfoxideHunner lesioninterstitial cystitisKRP-116Dpost hoc analysis

Identifiers

PMID34929761
PMCPMC9300131
OpenAlexW4200186854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.